Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats

Hypertension Research

Volumn 33, Issue 9, 2010, Pages 953-959

  Takai, Shinji ^a   Jin, Denan ^a   Sakonjo, Hiroshi ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

angiotensin II; angiotensin receptor blocker; calcium channel blocker; glomerulosclerosis; proteinuria

Indexed keywords

AMLODIPINE; COLLAGEN TYPE 1; EFONIDIPINE; IRBESARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PROTEIN P22; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG EFFICACY; GENE EXPRESSION; GLOMERULOSCLEROSIS; HIGH SODIUM INTAKE; MALE; NONHUMAN; PROTEINURIA; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHEMOKINE CCL2; COLLAGEN TYPE I; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; GENE EXPRESSION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HYPERTENSION; KIDNEY GLOMERULUS; MALE; NADPH OXIDASE; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; PROTEINURIA; RATS; RATS, INBRED DAHL; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA;

EID: 77956403931     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.90     Document Type: Article

References (38)

1. Anderson PW, Zhang XY, Tian J, Correale JD, Xi XP, Yang D etal. Insulin and angiotensin II are additive in stimulating TGF-P1 and matrix mRNAs in mesangial cells. Kidney Int 1996; 50: 745-753.
2. Pelayo JC, Quan AH, Shanley PF. Angiotensin II control of the renal microcirculation in rats with reduced renal mass. Am J Physiol 1990; 258: F414-F422.
3. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
4. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249: F324-F337.
5. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 1996; 19: 31-36.
6. Honda M, Hayashi K, Matsuda H, Kubota E, Tokuyama H, Okubo K et al. Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hypertens 2001; 19: 2031-2037.
7. Fujiwara K, Kanno Y, Hayashi K, Takenaka T, Saruta T. Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens 1998; 20: 295-312. (Pubitemid 28213250)
8. Kobori H, Nishiyama A, Abe Y, Navar LG. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 2003; 41: 592-597.
9. Wagner C, Kramer BK, Hinder M, Kieninger M, Kurtz A. T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. Br J Pharmacol 1998; 124: 579-585.
10. Takai S, Jin D, Ikeda H, Sakonjo H, Miyazaki M. Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats. Hypertens Res 2009; 32: 853-860.
11. Uehara Y, Hirawa N, Takeda T, Numabe A, Kawabata Y, Nagoshi H et al. Possible linkage between renal injury and cardiac remodeling in Dahl salt-sensitive rats treated with the calcium channel antagonist benidipine. Hypertens Res 1995; 18: 245-253.
12. Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y et al. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593-600.
13. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, FujitaT. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47: 1084-1093.
14. Remuzzi G, Perico N, Macia M, Ruggenenti P. The roleof renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int 2005; 99: S57-S65.
15. Nakaya H, Sasamura H, Mifune M, Shimizu-Hirota R, Kuroda M, Hayashi M et al. Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 2002; 91: 710-718.
16. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
17. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65: 30-39.
18. von Lutterotti N, Camargo MJ, Campbell Jr WG, Mueller FB, Timmermans PB, Sealey JE et al. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. J Hypertens 1992; 10: 949-957.
19. Imagawa K, Okayama S, Takaoka M, Kawata H, Naya N, Nakajima T et al. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 2006; 47: 133-138.
20. Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, Horie M. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res 2007; 30: 691-697.
21. Tsutamoto T, Tanaka T, Nishiyama K, Yamaji M, Kawahara C, Fujii M et al. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertens Res 2009; 32: 670-674.
22. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephri- tis. Hypertens Res 2007; 30: 621-626.
23. Sasaki H, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H et al. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. J Atheroscler Thromb 2009; 16: 568-575.
24. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16: 3306-3314.
25. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364.
26. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271: 17779-17784.
27. Fujii S, Zhang L, Kosaka H. Albuminuria, expression of nicotinamide adenine dinucleo- tide phosphate oxidase and monocyte chemoattractant protein-1 in the renal tubules of hypertensive Dahl salt-sensitive rats. Hypertens Res 2007; 30: 991-998.
28. Hansen PB, Jensen BL, Andreasen D, Skott O. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630-638.
29. Loutzenhiser RD, Epstein M, Fischetti F, Horton C. Effects of amlodipine on renal hemodynamics. Am J Cardiol 1989; 64: 122I-127I.
30. Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Saruta T. Effect of T-type selective calcium antagonist on renal microcirculation. Hypertension 2001; 38: 343-347.
31. Nakamura Y, Ono H, Frohlich ED. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertension 1999; 34: 273-278.
32. Masumiya H, Tanaka Y, Tanaka H, Shigenobu K. Inhibition of T-type and L-type Ca2+ currents by aranidipine, a novel dihydropyridine Ca2+ antagonist. Pharmacology 2000; 61: 57-61.
33. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263.
34. Saruta T, Kanno Y, Hayashi K, Konishi K. Antihypertensive agents and renal protection: calcium channel blockers. Kidney Int 1996; 55(Suppl): S52-S56.
35. Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A etal. The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol 2004; 15: 306-315.
36. Tian N, Moore RS, Phillips WE, Lin L, Braddy S, Pryor JS et al. NADPH oxidase contributes to renal damage and dysfunction in Dahl salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1858-R1865.
37. Tanaka T, Nangaku M, Miyata T, Inagi R, Ohse T, Ingelfinger JR et al. Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol 2004; 15: 2320-2333.
38. Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ et al. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. Am J Physiol Renal Physiol 2009; 297: F802-F808.